Komori
S

SAWAI GROUP HOLDINGS Co.,Ltd.

4887PharmaceuticalsMid cap
1,654JPY+1.1%
★ Watch (sign-up required)
Price history
¥1,654Latest+18.1%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group’s principal business is the manufacture and sale of pharmaceuticals in Japan and overseas through its domestic and overseas subsidiaries, as well as the management and support of their business activities. The Group consists of the Company and 6 consolidated subsidiaries. Its principal businesses are the manufacture and sale of prescription and over-the-counter pharmaceuticals. Sawai Pharmaceutical Co., Ltd. handles domestic sales, wholesale operations and direct sales to medical institutions. メディサ新薬株式会社 sells prescription pharmaceuticals, while Sawai Pharmaceutical Co., Ltd. undertakes part of its research and development and manufacturing operations. 化研生薬株式会社 manufactures and sells prescription pharmaceuticals, トラストファーマテック株式会社 manufactures and sells prescription pharmaceuticals, and FrontAct Co., Ltd. manufactures and sells medical equipment and other products. FrontAct Co., Ltd. is an affiliated subsidiary of Sumitomo Pharma Holdings, which also operates in the digital healthcare field. These affiliated companies are stated to be under 100% control.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
78.64How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.08How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
1.4%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥191bnShare price × number of shares. The value of the entire company.
Equity ratio
48.1%The proportion of assets funded by money that does not have to be repaid.
Operating margin
9.6%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
-0.9%The average annual growth in sales over the past three years.
What to watch next
Realisation of contract supply capacity through progress on new equipment installations at the second and third Seima plants, including commencement, completion and ramp-up
2027-2029 (range based on scheduled completion dates)Impact HighLikelihood Medium
Completion of the new solid-dose facility at Sawai Pharmaceutical’s Second Kyushu Plant, scheduled for January 2027, followed by the start of operations and contribution to shipments
Around January 2027Impact MediumLikelihood Medium
Evaluation of corrective and recurrence-prevention measures following the Kyushu plant’s quality-related regulatory action (improper dissolution testing), including regulatory confirmation and audit results
Impact HighLikelihood Medium
CureApp’s alcohol-dependence DTx under licence: sales performance following launch, including KPIs, recurring subscriptions and the number of installations
From September 2025 onward (currently in the early sales ramp-up phase)Impact MediumLikelihood Low
Progress toward market launch and revenue generation for Relivion, a non-invasive neuromodulation device, following marketing approval
Impact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 45.5%
Listed holders 45.5%Everyone else 54.5%
The Master Trust Bank of Japan, Ltd. (Trust Account)17.21%
株式会社日本カストディ銀行 (Trust Account)11.89%
Sawai Mitsuo (澤井 光郎)2.74%
BNYM AS AGT/CLTS 10 PERCENT（常任代理人 三菱UFJ銀行）2.57%
NORTHERN TRUST CO.（AVFC）RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST（常任代理人 HSBC東京支店）2.54%
澤井健造2.21%
Sumitomo Mitsui Banking Corporation1.68%
澤井光郎株式会社1.67%
2 other listed holders2.94%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)17.21
株式会社日本カストディ銀行 (Trust Account)11.89
Sawai Mitsuo (澤井 光郎)2.74
BNYM AS AGT/CLTS 10 PERCENT（常任代理人 三菱UFJ銀行）2.57
NORTHERN TRUST CO.（AVFC）RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST（常任代理人 HSBC東京支店）2.54
澤井健造2.21
Sumitomo Mitsui Banking Corporation1.68
澤井光郎株式会社1.67
2 other listed holders2.94
This company's documents
Filings
Timely disclosures
Threads